International Annual Patient Conference 2020
For more than a quarter-century, TMA (The Myositis Association) has provided the world’s largest myositis patient, care partner, industry, and global expert gathering at its Annual Patient Conference. This conference provides a unique opportunity for stakeholders to come together to address myositis research, technological advancements, clinical care best practices, support, resources, and the needs of myositis patients worldwide.
This year’s Annual Patient Conference theme, @Home, unites myositis patients virtually from around the world during this unprecedented time of Covid-19. The Myositis Association is excited to host their first Virtual International Annual Patient Conference.
Octapharma is pleased to be supporting the conference and hosting an exhibitor presence to raise awareness of Octapharma to this important patient community.
Fueled by direct feedback of thousands of attendees from previous conferences and TMA events, this robust 3-day Virtual Patient Conference is designed to inspire and empower patients with interactive sessions to encourage collaboration, socialization, and education. The conference being run during 11-13 September 2020 will move beyond a series of lectures by providing a unique platform for collaboration, socialization, education, and FUN!
The term “myositis” refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest. Other conditions that can cause muscle weakness and pain include infection, muscle injury from medications, inherited diseases, electrolyte imbalances, and thyroid disease.
More often, however, the term myositis is used to refer to a disease involving chronic inflammation of the muscles, often occurring together with other symptoms. This condition is also known as idiopathic inflammatory myopathy (IIM).
Types of Myositis
The disease is highly variable and has been classified into a number of forms, including:
· Dermatomyositis (DM)
· Polymyositis (PM)
· Necrotizing myopathy (NM)
· Sporadic inclusion body myositis (IBM)
· Juvenile forms of myositis (JM)
· Inflammatory Myopathies (IM)
Inflammatory myopathies are autoimmune diseases, meaning the body’s immune system, which normally fights infections and viruses, is misdirected and begins to attack the body’s own normal, healthy tissue. Inflammatory myopathies are rare diseases. All forms combined affect an estimated 50,000 to 75,000 people in the United States. While it is still unclear what causes myositis, some scientists believe certain individuals have a genetic predisposition to develop an autoimmune disease, which is triggered by an environmental exposure to some trigger, such as infection, virus, toxin, or sunlight.
Symptoms of weakness, swelling, and muscle damage often appear gradually. Long before patients are diagnosed, they may have trouble getting up from a chair, climbing stairs, or grasping objects with their hands. Patients may fall, find it difficult to reach their arms up, have difficulty swallowing, or other symptoms. In addition to these symptoms, it’s common for patients to experience other complications.
Myositis is often difficult to diagnose, because many physicians are unfamiliar with the disease and its symptoms. A typical diagnosis process for myositis patients begins with a medical history and physical examination. It may also include blood tests, muscle and skin biopsies, and a variety of other diagnostic tests.
Treatment and Disease Management
Myositis is a rare disease, so it is also difficult to conduct adequate research to test new treatments. There is a lot of confusion among the medical community over how to effectively manage patients with myositis. Nevertheless, myositis is a serious illness that, in most cases, needs to be treated aggressively. With inadequate or no treatment, myositis can cause significant disability and even death. There is no cure for any of the forms of myositis.
Octapharma is currently conducting a study in Dermatomyositis (DM) of which the results will be published very soon. For patients with Dermatomyositis, this is an encouraging development.